Epigenomics studies in Acute Myeloid Leukemia (AML)
|Study ID||Alternative Stable ID||Type|
Acute Myeloid Leukemia (AML) remains a clinical challenge since most patients diagnosed with AML will die from the disease. Some patients harbor treatment-refractory disease and others relapse with disease that in many cases is resistant to treatments. Our study was designed to understand the molecular basis of disease progression in AML through interrogation of patient samples collected through an international collaboration which assembled 138 paired (diagnosis and relapse) patient specimens.
It is hoped that this resource will help researchers understand mechanisms of disease relapse in AML and contribute to the general pool of data available for analyses for this disease and general research use.